The side effects of vigabatrin are in many respects similar to those reported for other standard antiepileptic drugs, the most common being drowsiness, dizziness, and irritability.' In a clinical trial we noted an increased incidence of depression in addition to the usually reported adverse effects. Four of the 33 patients entering this study were subsequently withdrawn with this complication.2 Furthermore, within the context of this trial mood rating scales showed an overall though
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Discussion
Most patients treated with vigabatrin show no noticeable change in mood, and some feel better because of better seizure control. However, a few develop depression after starting to take vigabatrin. To our knowledge, there has been no previous detailed account of the depression that may be associated with vigabatrin treatment, but in a review of 398 patients in nine placebo controlled clinical trials depression was reported in 4%, the sixth most common side effect.' The incidence of depression in our clinical trial was surprisingly high, four patients being withdrawn with this side effect out of 33 entered.2 To these four patients (cases 4-7) we have added six others in this report.
The patients fulfilled DSM IIIR criteria for a major depressive episode (table 3), which in each was closely related to the administration of vigabatrin. Seven patients developed depression within two months of starting vigabatrin treatment, during or soon after a dose increase. The remaining three patients had been taking the drug for between five and 30 months and the depression occurred within six weeks of a dose increase. In the former group (cases 1-7) the depression resolved soon after the withdrawal of vigabatrin. In those taking it for longer, who had been able to tolerate lower doses without depression, the affective disturbance improved while the dose of vigabatrin was being reduced. In two patients vigabatrin was cautiously reintroduced at a lower dose without causing depression but with some improvement in seizure control. Although the dose of vigabatrin at which depression developed varied between 1-5 g and 4 g (mean 2-85 g) a day, these observations suggest that the occurrence of depression was related to dose.
All 10 patients were assessed by a psychiatrist. The decision to withdraw vigabatrin was based on the view that it is better, when dealing with a possibly new side effect from a new drug to remove the potential cause than introduce an antidepressant in an attempt to control it.
The fact that only a few patients become depressed taking vigabatrin suggests that they may have a specific vulnerability to this complication. Analysis of the 10 patients in this series suggests a possible constitutional predisposition. No obvious psychosocial precipitants were apparent. Only two of the patients had a family history of depression, but it is striking that seven of the 10 patients had previous episodes of depression. Furthermore, in four of them (cases 2, 4, 5 and 9) previous depression had been provoked by phenobarbitone or the related barbiturate primidone. One of the patients had also developed aggressive behaviour while taking phenobarbitone (case 5). Aggressive behaviour is a prominent side effect of vigabatrin in children. 3 Vigabatrin may have induced depression in a vulnerable group through influencing seizure frequency or GABA metabolism, or both. An overview of the published short term studies on efficacy indicates that in general about half the patients receiving vigabatrin experience a fall in seizure frequency of more than half.4 Although most of our patients were not taking vigabatrin long enough to make definitive judgments about the effect of the drug on the frequency of their seizures, it is nevertheless striking that nine out of the 10 were experiencing a greater than 50% reduction in frequency when their depressive symptoms emerged. In six of them the reduction had occurred less than eight weeks before the onset of depression. A reciprocal relation between abnormal mental states and seizures has been commented on by several authors since the early observations by von Meduna and studies by Landolt.5 The neurophysiological concomitants of this relation were characterised from scalp electrocephalograms and described as "forced normalisation". However, Tellenbach used the term "alternative psychosis",6 which was a clinical expression and did not emphasise the electroencephalogram. We did not look for evidence of electroencephalographic normalisation, although the relation between depression and improved seizure control was obvious in some patients. Interestingly, although the reciprocal relation is most often described with psychosis, Wolf has described four patients in whom forced normalisation presented as an affective disorder.8 He notes that in his series psychiatric symptoms corresponded well with the patients' "primary personality". In this regard it was striking that seven of our 10 patients had a history of affective disturbance.
Another psychiatric association of vigabatrin-that is, the development of non-affective psychosis-may develop as an alternative state.9 Although Sander et al note that the mechanism of this effect is unknown, they suggest that it may relate to the powerful antiepileptic effect of vigabatrin in some patients,9 which may also apply in some of our patients.
A different explanation of the possible relation between vigabatrin treatment and depression relates to the specific mode of action of the drug-that is, dose dependent inhibition of y-amino butyric acid (GABA) transaminase with resulting increase in brain and cerebrospinal fluid GABA concentrations.1011 In the three patients in whom depression developed after a prolonged period of taking vigabatrin but shortly after a late dose increase (cases 8-10) there was no further improvement on the early good response to the treatment. This suggests that the observed mood changes in this group may be dose related rather than the result of changing seizure frequency. Earlier suggestions that GABA agonists may have antidepressant effects have not been confirmed.'2 13 Evidence that GABA concentrations in cerebrospinal fluid may be lower in depression is contradictory.14-20 Furthermore, experimental studies have shown that regional rather than widespread changes in GABA concentrations may be important for antiepileptic action.2' A similar mechanism may exist for mood changes, and hence these changes may not be reflected in total GABA concentrations in brain or cerebrospinal fluid. Our observations are compatible with the suggestion that increased GABAergic activity may depress mood in a few patients. In this context it is notable that antiepileptic drugs with some GABAergic activity-that is, barbiturates such as phenobarbitone and primidone and benzodiazepines such as clonazepamhave most often been associated with the development of depression in epilepsy.22 23 Benzodiazepines are also associated with depression in non-epileptic patients. 24 Further evidence of a role for GABA in provoking depressive symptoms comes from a study in which GABA was administered intravenously to normal volunteers.25 After the injection these subjects reported feelings of anxiety and lower mood. An animal model of human electroconvulsive therapy, repeated electroshock, led to a reduction in GABA release in the nucleus accumbens and the striatum. 26 Our observations of vigabatrin related depression therefore add to the evidence suggesting a role for GABA in the biology of mood disorders.
In summary, we have reported a series of 10 patients who became depressed in association with vigabatrin treatment. A history of an affective illness might predispose patients to this side effect. This effect may be related in individual patients to the dose of the drug. The development of depression, and perhaps other psychiatric disease, may be related either to the potency of the drug in controlling seizures or to its effect on GABA, or to both.
